<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005638</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/13</org_study_id>
    <nct_id>NCT04005638</nct_id>
  </id_info>
  <brief_title>Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia</brief_title>
  <acronym>BIOCAI</acronym>
  <official_title>Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Internal Medicine Department of Haut-Lévêque Hospital (Pr E LAZARO, Pr JL PELLEGRIN, Pr
      JF VIALLARD) was accredited in 2017 by the Ministry of Health as a Constitutive Reference
      Center for Autoimmune Cytopenia. The investigators wish to launch new research projects in
      autoimmune cytopenia and propose a translational and fundamental research based on
      collaboration between the clinical department, the biological resource center and the CNRS
      and INSERM research units (&quot;Bedside to the Bench Strategy&quot;). Thus, in the perspective of
      future research work, it seems imperative to set up a biological bank for the patients
      followed in our Reference Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our department follows about 350 patients with immune thrombocytopenia (ITP), 50 with
      autoimmune hemolytic anemia (AHA), and about thirty patients for autoimmune neutropenia and
      erythroblastopenia. The number of new patients per year is about 50. The investigators are
      working since several years on different research topics concerning ITP and AHA.

      In the field of ITP, the investigators are working on abnormalities of megakaryopoiesis
      present in a particular subgroup of patients. The investigators seek to identify the
      molecular mechanisms underlying this platelet-forming disorder. This research is done within
      the INSERM U1034 unit of the University of Bordeaux.

      In AHA, The investigators are working on the role of regulatory CD8+ T lymphocytes and the
      interest of low doses of Interleukin-2 in their treatment. This part is carried out within
      the CNRS unit UMR 5164 ImmunoConcept. The biological collection the investigators wish to
      create will be available for basic research projects and may be available to the
      pharmaceutical industry as part of the development of new molecules.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with autoimmune cytopenia at diagnosis, or followed but not treated with a biological library (serum, plasma, DNA)</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Autoimmune Neutropenia</condition>
  <arm_group>
    <arm_group_label>Autoimmune Cytopenia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>Autoimmune Cytopenia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>urine sample</intervention_name>
    <description>12 ml</description>
    <arm_group_label>Autoimmune Cytopenia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and
      urine sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with autoimmune cytopenia according to the definitions reported in the latest
        update of the French National Care Protocol (PNDS 2017).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 16 years old.

          -  Patients with autoimmune cytopenia according to the definitions reported in the latest
             update of the French National Care Protocol (PNDS 2017).

          -  Affiliated person or beneficiary of a social security scheme.

          -  Free, informed and written consent signed by the participant and the investigator (at
             the latest on the day of inclusion and before any examination required by the
             research).

        Exclusion Criteria:

          -  Positivity for HIV, Hepatitis C or B virus.

          -  Pregnant or lactating woman.

          -  Patient undergoing treatment for autoimmune cytopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François VIALLARD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU - Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François VIALLARD, Prof</last_name>
    <phone>05.57.65.64.83</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-françois.viallard@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle RAYMOND, Pharm</last_name>
    <email>isabelle.raymond@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de médecine interne</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <phone>05.57.65.64.83</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-françois.viallard@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle RAYMOND, Pharm</last_name>
      <email>isabelle.raymond@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc PELLEGRIN, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine GREIB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene MACHELARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne RIVIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biological collection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

